1. NAME OF THE VETERINARY MEDICINAL PRODUCT
ZACTRAN 150 mg/ml solution for injection for cattle, sheep and pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains:

**Active substance:**
Gamithromycin 150 mg

**Excipient:**
Monothioglycerol 1 mg

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Solution for injection.
Colourless to pale yellow solution.

4. CLINICAL PARTICULARS

4.1 Target species
Cattle, sheep and pigs.

4.2 Indications for use, specifying the target species

Cattle:
Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida* and *Histophilus somni*. The presence of the disease in the herd should be established before metaphylactic use.

Pigs:
Treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Haemophilus parasuis* and *Bordetella bronchiseptica*.

Sheep:
Treatment of infectious pododermatitis (foot rot) associated with virulent *Dichelobacter nodosus* and *Fusobacterium necrophorum* requiring systemic treatment.

4.3 Contraindications
Do not use in cases of hypersensitivity to macrolide antibiotics or to any of the excipients.
Do not use this veterinary medicinal product simultaneously with other macrolides or lincosamides (see section 4.8).

4.4 Special warnings for each target species

Cattle and pigs:
None.

Sheep:
The efficacy of antimicrobial treatment of foot rot might be reduced by other factors, such as wet environmental conditions, as well as inappropriate farm management. Treatment of foot rot should therefore be undertaken along with other flock management tools, for example providing dry environment. Antibiotic treatment of benign foot rot is not considered appropriate.

4.5 Special precautions for use

Special precautions for use in animals

Use of the veterinary medicinal product should be based on susceptibility testing and take into account official and local policies on the use of antimicrobials in farm animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to the macrolide class should avoid contact with the veterinary medicinal product. Gamithromycin may cause irritation to eyes and/or skin. Avoid contact with skin or eyes. If eye exposure occurs, flush eyes immediately with clean water. If skin exposure occurs, wash the affected area immediately with clean water. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after use.

4.6 Adverse reactions (frequency and seriousness)

During clinical trials transient injection site swellings were observed.

- Visible injection site swellings associated with occasional slight pain may develop very commonly in cattle for one day. The swellings typically resolve within 3 to 14 days but may persist in some animals for up to 35 days after treatment.
- Mild to moderate injection site swelling has been reported commonly in sheep and pigs in clinical trials, with occasional slight pain evident for one day in sheep. These local reactions are transient, and typically resolve within 2 (pigs) to 4 (sheep) days.

The frequency of adverse reactions is defined using the following convention:

- Very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- Common (more than 1 but less than 10 animals in 100 animals treated)
- Uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- Rare (more than 1 but less than 10 animals in 10,000 animals treated)
- Very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Based on laboratory animal data, gamithromycin has not produced any evidence of specific developmental or reproductive effects. The safety of gamithromycin during pregnancy and lactation has not been evaluated in cattle, sheep and pigs. Use only according to the risk/benefit assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

Cross resistance may occur with other macrolides. Avoid simultaneous administration of antimicrobials with a similar mode of action such as other macrolides or lincosamides.
4.9 Amounts to be administered and administration route

A single dose of 6 mg gamithromycin/kg body weight (equivalent to 1 ml/25 kg body weight) into the neck (cattle and pigs) or anterior to the shoulder (sheep). To ensure correct dose, body weight should be determined as accurately as possible to avoid underdosing.

**Cattle and sheep**

Subcutaneous injection. For treatment of cattle over 250 kg and sheep over 125 kg body weight, divide the dose so that no more than 10 ml (cattle) or 5 ml (sheep) are injected at a single site.

**Pigs**

Intramuscular injection. The injection volume should not exceed 5 ml per injection site.

The cap may be safely punctured up to 60 times. For multiple vial entry, an automatic dosing device is recommended to avoid excessive broaching of the stopper.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Clinical studies have demonstrated the wide margin of safety for gamithromycin injection in the target species. In young adult cattle, sheep and pig studies, gamithromycin was administered by injection at 6, 18, and 30 mg/kg (1, 3, and 5 times the recommended dose) and repeated three times at 0, 5 and 10 days (three times the recommended duration of use). Injection site reactions were noted in a dose related manner.

4.11 Withdrawal period(s)

**Meat and offal:**
- Cattle: 64 days
- Sheep: 29 days
- Pigs: 16 days

Not authorised for use in lactating animals producing milk for human consumption. Do not use in pregnant animals which are intended to produce milk for human consumption within 2 months (cows, heifers) or 1 month (ewes) of expected parturition.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antibacterials for systemic use, macrolides

ATC vet code: QJ01FA95.

5.1 Pharmacodynamic properties

Gamithromycin is an azalide, 15-membered semisynthetic macrolide class antibiotic with uniquely positioned alkylated nitrogen at 7a-position of the lactone ring. This special chemistry facilitates rapid absorption at physiological pH and a long duration of action at the target tissues, the lung and the skin. Macrolides in general have both bacteriostatic and bactericidal action mediated through disruption of bacterial protein synthesis. Macrolides inhibit bacterial protein biosynthesis by binding to the 50S ribosomal subunit and by preventing peptide chain elongation. The in vitro data show that gamithromycin acts in a bactericidal manner. The broad spectrum antimicrobial activity of gamithromycin includes *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, *Actinobacillus pleuropneumoniae*, *Haemophilus parasuis* and *Bordetella bronchiseptica*, the bacterial pathogens most commonly associated with BRD and SRD, and also *Fusobacterium necrophorum* and *Dichelobacter nodosus*. The MIC and MBC data (cattle and pig) are reported from a representative sample of isolates from field materials within different EU geographic areas.
Cattle | MIC<sub>90</sub> | MBC<sub>90</sub> | µg/ml | µg/ml
---|---|---|---|---
*Mannheimia haemolytica* | 0.5 | 1 | |
*Pasteurella multocida* | 1 | 2 | |
*Histophilus somni* | 1 | 2 | |

Pigs | MIC<sub>90</sub> | MBC<sub>90</sub> | µg/ml | µg/ml
---|---|---|---|---
*Actinobacillus pleuropneumoniae* | 4 | 4 | |
*Pasteurella multocida* | 1 | 2 | |
*Haemophilus parasuis* | 0.5 | 0.5 | |
*Bordetella bronchiseptica* | 2 | 4 | |

Sheep | MIC | µg/ml | MIC<sub>90</sub> | 32 | 0.008 – 0.016
---|---|---|---|---|---
*Fusobacterium necrophorum* | | | |
*Dichelobacter nodosus* | | | |

Three mechanisms are generally considered responsible for resistance to the macrolide class of compounds. This is often referred to as MLS<sub>B</sub> resistance as it affects macrolides, lincosamides and streptogramins. The mechanisms involve the alteration of the ribosomal target site, the utilization of active efflux mechanism and the production of inactivating enzymes.

### 5.2 Pharmacokinetic particulars

**Cattle**
Gamithromycin administered subcutaneously into the neck of cattle at a single dose of 6 mg/kg body weight, resulted in rapid absorption with peak plasma concentrations observed after 30 to 60 min with a long plasma half-life (> 2 days). The bioavailability of the compound was > 98 % with no gender differences. The volume of distribution at steady-state was 25 l/kg. Gamithromycin levels in lung reached a maximum in less than 24 hr, with lung-to-plasma ratio of > 264 indicating that gamithromycin was absorbed rapidly into the target tissue for BRD.

*In vitro* plasma protein binding studies determined that the mean concentration of the free active substance was 74 %. Biliary excretion of the unchanged drug substance was the major route of elimination.

**Pigs**
Gamithromycin administered intramuscularly in pigs at single dose of 6 mg/kg body weight, resulted in rapid absorption with peak plasma concentrations observed after 5 to 15 min, with a long plasma half-life (about 4 days). The bioavailability of gamithromycin was > 92 %. The compound is absorbed rapidly into the target tissue for SRD. Accumulation of gamithromycin in the lung has been demonstrated by high and sustained concentrations in the lung and bronchial fluid which far exceed those in blood plasma. The volume of distribution at steady-state was approximately 39 l/kg. *In vitro* plasma protein binding studies determined that the mean concentration of the free active drug was 77 %. Biliary excretion of the unchanged drug was the major route of elimination.

**Sheep**
Gamithromycin administered subcutaneously into the neck of sheep at a single dose of 6 mg/kg body weight is rapidly absorbed, and maximum plasma concentrations were observed between 15 minutes and 6 hours after dosing (2.30 hours on average) with high absolute bioavailability of 89%.
Gamithromycin skin concentrations were much higher than the plasma concentrations resulting in skin/plasma concentration ratios of approximately 21, 58, and 138 at two, five and ten days post-dosing, respectively, demonstrating extensive distribution and accumulation in skin tissue.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Monothioglycerol
Succinic Acid
Glycerol Formal

6.2 Major incompatibilities
In the absence of compatibility studies, this veterinary medicinal product should not be mixed with other veterinary medicinal products.

6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 28 days.

6.4 Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.

6.5 Nature and composition of immediate packaging
Type 1 glass vial of 50, 100, 250 or 500 ml with a chlorobutyl rubber stopper, a polypropylene cap and an aluminium crimp seal.
Polypropylene vial of 100, 250 or 500 ml with a chlorobutyl rubber stopper, a polypropylene cap and an aluminium crimp seal.
Cardboard box containing 1 vial of 50, 100, 250 or 500 ml.
The 500 ml vial is for cattle and pigs only.
Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER
MERIAL
29, avenue Tony Garnier
69007 Lyon
France
8. MARKETING AUTHORISATION NUMBER(S)

EU/2/08/082/001
EU/2/08/082/002
EU/2/08/082/003
EU/2/08/082/004
EU/2/08/082/005
EU/2/08/082/006
EU/2/08/082/007

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 24/07/2008
Date of last renewal: 15/07/2013

10. DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.
ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE

C. STATEMENT OF THE MRLs

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

MERIAL
4, Chemin du Calquet
31000 Toulouse
France

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE

Veterinary medicinal product subject to prescription.

C. STATEMENT OF THE MRLs

The active substance in ZACTRAN 150 mg/ml solution for injection for cattle, sheep and pigs is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:

<table>
<thead>
<tr>
<th>Pharmaco-logically active substance</th>
<th>Marker residue</th>
<th>Animal species</th>
<th>MRL</th>
<th>Target tissues</th>
<th>Other provisions</th>
<th>Therapeutic classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamithromycin</td>
<td>Gamithromycin</td>
<td>Bovine</td>
<td>20 μg/kg</td>
<td>Fat</td>
<td>Not for use in animals producing milk for human consumption</td>
<td>Anti-infectious agents / Antibiotics</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200 μg/kg</td>
<td>Liver</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>100 μg/kg</td>
<td>Kidney</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Porcine</td>
<td></td>
<td></td>
<td>100 μg/kg</td>
<td>Muscle</td>
<td>NO ENTRY</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>100 μg/kg</td>
<td>Skin and fat in natural proportions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>100 μg/kg</td>
<td>Liver</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>300 μg/kg</td>
<td>Kidney</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovine</td>
<td></td>
<td></td>
<td>50 μg/kg</td>
<td>Muscle</td>
<td>Not for use in animals producing milk for human consumption</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50 μg/kg</td>
<td>Fat</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>300 μg/kg</td>
<td>Liver</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200 μg/kg</td>
<td>Kidney</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required.

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Specific pharmacovigilance requirements:

The periodic safety update report (PSUR) cycle should be re-started for submission of 6-monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

ZACTRAN 150 mg/ml solution for injection for cattle, sheep and pigs gamithromycin

2. **STATEMENT OF ACTIVE SUBSTANCES**

1 ml contains 150 mg of gamithromycin.

3. **PHARMACEUTICAL FORM**

Solution for injection

4. **PACKAGE SIZE**

50 ml
100 ml
250 ml

5. **TARGET SPECIES**

Cattle, sheep, pigs

6. **INDICATION(S)**

7. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle and sheep: Subcutaneous use
Pigs: Intramuscular use
Read the package leaflet before use.

8. **WITHDRAWAL PERIOD(S)**

Withdrawal periods:
Meat and offal: Cattle: 64 days. Sheep: 29 days. Pigs: 16 days.
Not authorised for use in lactating animals producing milk for human consumption.
Do not use in pregnant animals which are intended to produce milk for human consumption, within 2 months (cows, heifers) or 1 month (ewes) of expected parturition.

9. **SPECIAL WARNING(S), IF NECESSARY**
10. **EXPIRY DATE**

EXP
Shelf life after first opening the container: 28 days
Once opened, use by __/__/__

11. **SPECIAL STORAGE CONDITIONS**

12. **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

13. **THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

14. **THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

15. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merial
29 avenue Tony Garnier
69007 Lyon
France

16. **MARKETING AUTHORISATION NUMBER(S)**

EU/2/08/082/001
EU/2/08/082/002
EU/2/08/082/004
EU/2/08/082/005
EU/2/08/082/007

17. **MANUFACTURER’S BATCH NUMBER**

Lot
PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box (500 ml)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

ZACTRAN 150 mg/ml solution for injection for cattle and pigs
gamithromycin

2. STATEMENT OF ACTIVE SUBSTANCES

1 ml contains 150 mg of gamithromycin,

3. PHARMACEUTICAL FORM

Solution for injection

4. PACKAGE SIZE

500 ml

5. TARGET SPECIES

Cattle, pigs

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Cattle: Subcutaneous use
Pigs: Intramuscular use
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal periods:
Meat and offal: Cattle: 64 days. Pigs: 16 days.
Not authorised for use in lactating animals producing milk for human consumption.
Do not use in pregnant cows and heifers which are intended to produce milk for human consumption, within 2 months of expected parturition.

9. SPECIAL WARNING(S), IF NECESSARY
10. EXPIRY DATE

EXP
Shelf life after first opening the container: 28 days
Once opened, use by __/__/__

11. SPECIAL STORAGE CONDITIONS

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MERIAL
29 avenue Tony Garnier
69007 Lyon
France

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/08/082/003
EU/2/08/082/006

17. MANUFACTURER’S BATCH NUMBER

Lot
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGE UNITS
VIAL 50 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
ZACTRAN 150 mg/ml solution for injection for cattle, sheep and pigs
gamithromycin

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)
1 ml contains 150 mg of gamithromycin

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
50 ml

4. ROUTE(S) OF ADMINISTRATION
SC (cattle, sheep), IM (pigs)

5. WITHDRAWAL PERIOD(S)
Withdrawal periods: Meat and offal: Cattle: 64 days. Sheep: 29 days. Pigs: 16 days
Not authorised for use in animals producing milk for human consumption.

6. BATCH NUMBER
Lot

7. EXPIRY DATE
EXP
Once opened, use by __/__/__

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
### PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

**VIAL 100 ml, 250 ml**

<table>
<thead>
<tr>
<th>1. NAME OF THE VETERINARY MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZACTRAN 150 mg/ml solution for injection for cattle, sheep and pigs gamithromycin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCES</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 ml contains 150 mg of gamithromycin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. PHARMACEUTICAL FORM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solution for injection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PACKAGE SIZE</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 ml</td>
</tr>
<tr>
<td>250 ml</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. TARGET SPECIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle, sheep, pigs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. INDICATION(S)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>7. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC (cattle, sheep) IM (pigs)</td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. WITHDRAWAL PERIOD(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Withdrawal period(s):</td>
</tr>
<tr>
<td>Meat and offal: Cattle: 64 days. Sheep: 29 days. Pigs: 16 days</td>
</tr>
<tr>
<td>Not authorised for use in animals producing milk for human consumption.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

17
<table>
<thead>
<tr>
<th>10. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP&lt;br&gt;Once opened, use by <strong>/</strong>/__</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11. SPECIAL STORAGE CONDITIONS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>For animal treatment only. To be supplied only on veterinary prescription.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>15. NAME AND ADDRESS OF THE MARKETING AUTHORITY HOLDERMERIAL&lt;br&gt;29 avenue Tony Garnier&lt;br&gt;69007 Lyon&lt;br&gt;France</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>16. MARKETING AUTHORIZATION NUMBER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/2/08/082/001&lt;br&gt;EU/2/08/082/002&lt;br&gt;EU/2/08/082/004&lt;br&gt;EU/2/08/082/005</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17. MANUFACTURER’S BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIAL 500 ml</td>
</tr>
</tbody>
</table>

1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

ZACTRAN 150 mg/ml solution for injection for cattle and pigs gamithromycin

2. **STATEMENT OF ACTIVE SUBSTANCES**

1 ml contains 150 mg of gamithromycin,

3. **PHARMACEUTICAL FORM**

Solution for injection

4. **PACKAGE SIZE**

500 ml

5. **TARGET SPECIES**

Cattle, pigs

6. **INDICATION(S)**

7. **METHOD AND ROUTE(S) OF ADMINISTRATION**

SC (cattle) IM (pigs)
Read the package leaflet before use.

8. **WITHDRAWAL PERIOD(S)**

Withdrawal period(s):
Meat and offal: Cattle: 64 days. Pigs: 16 days
Not authorised for use in animals producing milk for human consumption.
9. SPECIAL WARNING(S), IF NECESSARY

10. EXPIRY DATE

EXP
Once opened, use by __/__/__

11. SPECIAL STORAGE CONDITIONS

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MERIAL
29 avenue Tony Garnier
69007 Lyon
France

16. MARKETING AUTHORIZATION NUMBER(S)

EU/2/08/082/003
EU/2/08/082/006

17. MANUFACTURER’S BATCH NUMBER

Lot
B. PACKAGE LEAFLET
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Merial
29 avenue Tony Garnier
69007 Lyon
France

Manufacturer responsible for batch release:
Merial
4, Chemin du Calquet
31000 Toulouse
France

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

ZACTRAN 150 mg/ml solution for injection for cattle, sheep and pigs
Gamithromycin

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS

1 ml contains
Active substance: 150 mg of gamithromycin
Excipients: 1 mg of monothioglycerol
Colourless to pale yellow solution.

4. INDICATION(S)

Cattle:
Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
The presence of the disease in the herd should be established before metaphylactic use.

Pigs:
Treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Bordetella bronchiseptica.

Sheep:
Treatment of infectious pododermatitis (foot rot) associated with virulent Dichelobacter nodosus and Fusobacterium necrophorum requiring systemic treatment.

5. CONTRAINDICATIONS

Do not use in case of hypersensitivity to a certain type of antibiotics called macrolides or to any of the excipients.
Do not use this veterinary medicinal product simultaneously with other macrolides or antibiotics known as lincosamides.
6. ADVERSE REACTIONS

During clinical trials transient injection site swellings were observed.

- Visible injection site swellings associated with occasional slight pain may develop very commonly in cattle for one day. The swellings typically resolve within 3 to 14 days but may persist in some animals for up to 35 days after treatment.
- Mild to moderate injection site swelling has been reported commonly, in sheep and pigs in clinical trials, with occasional pain evident for one day in sheep. These local reactions are transient and typically resolve within 2 (pigs) to 4 (sheep) days.

The frequency of adverse reactions is defined using the following convention:

- Very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- Common (more than 1 but less than 10 animals in 100 animals treated)
- Uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- Rare (more than 1 but less than 10 animals in 10,000 animals treated)
- Very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Cattle, sheep and pigs.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

A single dose of 6 mg gamithromycin/kg body weight (equivalent to 1 ml/25 kg body weight) into the neck (cattle and pigs) or anterior to the shoulder (sheep).

Cattle and sheep: subcutaneous injection. For treatment of cattle over 250 kg and sheep over 125 kg body weight, divide the dose so that no more than 10 ml (cattle) and 5 ml (sheep) are injected at a single site.

Pigs: intramuscular injection. The injection volume should not exceed 5 ml per injection site.

The cap may be safely punctured up to 60 times. For multiple vial entry, an automatic dosing device is recommended to avoid excessive broaching of the stopper.

9. ADVICE ON CORRECT ADMINISTRATION

To ensure correct dose, body weight should be determined as accurately as possible to avoid underdosing.

The efficacy of antimicrobial treatment of foot rot might be reduced by others factors, such as wet environmental conditions, as well as inappropriate farm management. Treatment of foot rot should therefore be undertaken along with other flock management tools, for example providing dry environment. Antibiotic treatment of benign foot rot is not considered appropriate.

10. WITHDRAWAL PERIOD(S)

Meat and offal: Cattle: 64 days. Sheep: 29 days. Pigs: 16 days

Not authorised for use in lactating animals producing milk for human consumption.

Do not use in pregnant animals which are intended to produce milk for human consumption, within 2 months (cows, heifers) or 1 month (ewes) of expected parturition.
11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the vial after EXP. Shelf-life after first opening the container: 28 days.

12. SPECIAL WARNING(S)

Special precautions for use in animals:
Use of the veterinary medicinal product should be based on susceptibility testing and take into account official and local policies on the use of antimicrobials in farm animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to the macrolide class should avoid contact with the veterinary medicinal product.

Gamithromycin may cause irritation to eyes and/or skin. Avoid contact with skin or eyes. If eye exposure occurs, flush eyes immediately with clean water. If skin exposure occurs, wash the affected area immediately with clean water.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Pregnancy and lactation:
The safety of gamithromycin during pregnancy and lactation has not been evaluated in cattle, sheep and pigs. Use according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:
Cross resistance may occur with other macrolides. Avoid simultaneous administration of antimicrobials with a similar mode of action such as other macrolides or lincosamides.

Overdose:
In young adult cattle, sheep and pig studies, gamithromycin was administered by injection at 6, 18, and 30 mg/kg (1, 3, and 5 times the recommended dose) and repeated three times at 0, 5 and 10 days (three times the recommended duration of use). Injection site reactions were noted in a dose related manner.

Incompatibilities:
Do not mix with other medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED


15. OTHER INFORMATION

Cardboard box containing 1 vial of 50, 100, 250 or 500 ml.
The 500 ml vial is for cattle and pigs only.
Not all pack sizes may be marketed.